June 8, 2022 7:37am

It’s electronic trading and algorithms, not investors who are motivating and then undermining the share pricing

Pre-open indications: 3 Upside Indications, 5 Downside Indications, 2 Sell into Strength, 1 Puff/Pump/Promote

RMi outlines a daily bell ringing of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.

The 7:45 A.M., ET edition

Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.


Dow futures are DOWN -0.35% (-115 points), S&P futures are DOWN -0.25% (-10 points) and NASDAQ futures are DOWN -0.12% (-15 points) early in the pre-open – so far,


Stock futures fell Wednesday after two consecutive days of gains,

European stocks fell as investors digested a profit warning from Credit Suisse and prepared for the European Central Bank’s latest policy decision,

Asia-Pacific were higher with Hong Kong leading gains regionally as Japan’s economy shrank an annualized 0.5% in Q1.



U.S. stocks rallied Tuesday as treasury yields eased, but indexes remain “wonky” as investors wait for Friday’s Fed revelations on where interest rates, inflation and the economy are heading.

Investors seem to be shrugging-off economic flash-points (gas, food and staples etc.) and slowdown ahead of Friday’s key inflation reading.

Tuesday, the Dow advanced more than 264.36 points or +0.80%, the Nasdaq rose +113.86 or +0.94% as the S&P 500 gained +39.ts or +0.95%, rising for a second straight day.

Economic Data Docket: Mortgage demand falls to the lowest level in 22 years, amid rising rates and slowing home sales …

All eyes will be on Friday’s consumer price index reading for May. Many believe the print will be crucial for the path of Fed policy and whether the central bank will keep raising rates in 50-basis-point increments. <CNBC>


RegMed Investors’ (RMi) closing bell: “I thought up/downs was an exercise.  As the cell and gene therapy sector jumps back to its feet … https://www.regmedinvestors.com/articles/12463

Ebb and flow –

Q2/22 –

June – 3 positive and 2 negative closes

·         May - 11 positive and 10 negative closes

·         April - 1 holiday, 6 positive and 13 negative closes


·         March – 13 negative and 10 positive closes

·         February stats: 11 negative, 8 positive closes and 1 holiday

·         January stats: 2 holidays, 1 neutral, 13 negative and 6 positive closes


Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS

Exhibiting negative indications:

Beam Therapeutics (BEAM) closed up +$2.63 to $38.52 after Monday’s -$1.39 <52-week low of $27.77> after Friday’s -$0.43 with a negative -$1.09 or -2.83% pre-open indication,

Chinook Therapeutics (KDNY) closed up +$0.87 to $17.25 after Monday’s -$1.05, Friday’s +$1.41, Thursday’s -$1.41 and last Wednesday’s -$1.39 with negative -$0.65 or -3.77% pre-open indication,

Editas Medicine (EDIT) closed up +$0.90 to $12.49 after Monday’s -$0.32, Friday’s +$0.37, Thursday’s +$0.57 and last Wednesday’s -$0.42 with a negative -$0.32 or -2.56% pre-open indication,

Regenxbio (RGNX) closed up +$1.20 to $23.23 <52-week low of $18.69> after Monday’s -$0.81 with a negative -$1.16 or -4.99% pre-open indication,

MiMedx (MDXG) closed up +$0.12 to $3.96 with a negative -$0.19 or -4.80% pre-open indication as shareholders have approved all proposals set forth by the company at the 2022 Annual Meeting of Shareholders, including the reelection of both of MDXG’s directors, Dr. Phyllis Gardner and James L. Bierman, and the proposals on say-on-pay and the qualified employee stock purchase plan.


Exhibiting positive indication:

Alnylam Pharmaceuticals (ALNY) closed up +$2.38 to $134.01 after Monday’s +$0.11 with a positive +0.21 or +0.16% pre-open indication,

Caribou Biosciences (CRBU) closed up +$0.64 to $8.92 <52-week low of $6.41> after Monday’s -$0.46 with a positive +$0.44 or +4.93% pre-open indication

Mesoblast (MESO) closed flat at $3.06 after Monday’s -$0.26 <52-week low of $3.03> after Friday’s -$0.09 with a positive +$0.15 or +4.90% pre-open indication,


Sell into Strength:

bluebird bio (BLUE) closed up +$0.63 to $3.61 after Monday’s -$0.18 with a positive +$0.06 or +1.66% pre-open indication,

Verve Therapeutics (VERV) closed up +$1.18 to $14.72 after Monday’s -$1.04 <52-week low of $11.30 and a high of $78.00> after Friday’s -$0.10 with a positive +$0.03 or +0.20% re-open indication,


Puff/Pump and Promote: Maintaining SELL

Biostage (OTCQB: BSTG) closed flat at $4.68 with 65 shares traded after Monday’s +$0.23 with 3,575 shares traded after Friday’s -$0.33 with 250 shares traded, Thursday’s flat with 1 share traded, and last Wednesday’s -$0.37 to $4.75 with 100 shares traded.

  • WARNING:  Earnings reported a VERY SAD picture of a company’s status without U.S investors and reliance on non-U.S. Chinese investors. Another PPM -private placement – this one for $5.1 M without a price per share notification. Also, the terminal death lawsuit just got settled (4/28) for $6 M with a PPM – a preferred convertible debt financing.  is it the ONLY avenue to finance utilizing non-U.S. Chinese investors?

·         So, Has BSTG filed its Annual Report to the FDA, isn’t it a “Material Fact”?


The BOTTOM LINE: Monday’s losses (advance/decline line of 11/23 and 1 flat) were offset by Tuesday’s 30 incliner, 3 decliners and 2 flats as compared to last Friday’s 27 incliner and 8 decliners.

The stock market rally hasn't quite figured out if it wants to move higher or test May's lows while the cell and gene therapy sector doesn’t actually translate into positive or negative trading cycles.

I don’t hear the bugle sound of an advance or rally … rising rates and slowing economic growth are not a supportive environment for investors.

Again, as have I written (repeatedly), “There's a battle in the cell and gene therapy sector between which or what breaks first: share pricing resilience or tumbling into yet another downturn as fear remains beneath the strength of any positive close” …

This continuing state of volatility confirms fears that I have been expressing in these daily and weekly posts.

What changes …

I have NOT seen ANY step-up of declining company investment by ANY CEOs and their management teams – WHY NOT?

I try to keep it simple … and short!

I caution investors that the severe share pricing’s – technical and fundamental damage has been suffered these past several months which will take longer than a few good sessions to repair.

Whether information or intelligence is good, bad or somewhere in between; RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.


Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.